Company news
AB Science SA news in 2025
AB Science SA's news releases, calls and decks from 2025, newest first.
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040
December 22, 2025
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share
December 18, 2025
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers
December 15, 2025
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function
December 11, 2025
AB Science announces the successful completion of a EUR 2.8 million private placement
October 17, 2025
AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
October 16, 2025
AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939
October 14, 2025
AB Science today reports its revenues for the first half of 2025 and provides an update on its activities
October 10, 2025
AB Science announces a slight delay in the publication of its 2025 half-year financial report
September 30, 2025
AB Science announces the successful completion of a 2.55 million euros private placement
August 4, 2025
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
July 30, 2025
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
July 24, 2025
AB Science announces the successful completion of a EUR 1.925 million private placement
July 8, 2025
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
July 4, 2025
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
June 30, 2025
AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
June 23, 2025
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036
June 12, 2025
AB Science announces EMA approval of Masivet shelf-life extension to 4 years
June 9, 2025
AB Science announces the settlement delivery of its latest capital increase for €1.8 million
May 23, 2025
AB Science announces the successful completion of a EUR 1.8 million private placement
May 20, 2025
AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection
May 19, 2025
AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib
May 15, 2025
AB Science reports its revenues for the year 2024 and provides an update on its activities
May 12, 2025
AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting
May 5, 2025
AB Science will publish its 2024 annual financial report on May 9, 2025
May 1, 2025
AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia
April 23, 2025
Decks in 2025
- Investor Presentation (March 2025)
Investor deck · 59 slides · March 2025